	US 12,252,478 B2
	Crystalline forms of N-[4-(chlorodifluoromethoxy)phenyl]-6-[(3R)-3-hydroxypyrrolidin-1-yl]-5-(1H-pyrazol-5-yl)pyridine-3-carboxamide
Stephanie Kay Dodd, Ayer, MA (US); Arnaud Grandeury, Helfrantzkirch (FR); Emmanuel Suffert, Basel (CH); and Evgenia Rousaki, Basel (CH)
Assigned to Novartis AG, Basel (CH)
Filed by NOVARTIS AG, Basel (CH)
Filed on Jul. 6, 2022, as Appl. No. 17/858,701.
Application 17/858,701 is a continuation of application No. 16/874,622, filed on May 14, 2020, granted, now 11,407,735.
Claims priority of provisional application 62/949,599, filed on Dec. 18, 2019.
Claims priority of provisional application 62/848,857, filed on May 16, 2019.
Prior Publication US 2023/0089503 A1, Mar. 23, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 401/14 (2006.01); A61K 9/20 (2006.01)

CPC C07D 401/14 (2013.01) [A61K 9/20 (2013.01); C07B 2200/13 (2013.01)]

23 Claims

1. A pharmaceutical composition comprising:

(a) a therapeutically effective amount of a crystalline form A of asciminib hydrochloride; and

(b) at least one pharmaceutically acceptable carrier, diluent, vehicle or excipient, wherein the crystalline form A of asciminib hydrochloride is characterized by having an x-ray powder diffraction pattern comprising reflections at 2-Theta angles of 12.6±0.2°, 18.9±0.2° and 20.9±0.2°, when measured at a temperature in the range of from 20 to 25° C. with Cu-Kalpha1,2 radiation having a wavelength of 0.1541 Å.